3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
10
Phase 1
6
Phase 1/2
3
Phase 3
2
Status
Recruiting
6
Active not recruiting
5
Completed
2
Not yet recruiting
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Lymphoid
2
Other hematologic neoplasm
1
Conditions
Waldenstrom Macroglobulinemia
1
Recurrence
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Interventions
Cyclophosphamide
298
Cisplatin
298
Paclitaxel
257
Radiotherapy
254
Fluorouracil
234
Carboplatin
234
Docetaxel
230
Doxorubicin
214
Dexamethasone
166
Gemcitabine
156
Vincristine
145
Etoposide
135
Leucovorin
133
Capecitabine
129
Bevacizumab
129
Prednisone
125
Rituximab
118
Methotrexate
118
Cytarabine
110
Filgrastim
99
Trastuzumab
97
Oxaliplatin
96
pembrolizumab
83
Pemetrexed
73
Epirubicin
70
Tamoxifen
69
Drug Therapy
69
Irinotecan
65
Granulocyte Colony-Stimulating Factor
60
Daunorubicin
58
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 3
×
Completed
×
zanubrutinib
×
Clear all
NCT03734016
2025-03-30
ALPINE
BeiGene
Phase 3
Completed
652 enrolled
27 charts
1 FDA
NCT03053440
2024-10-26
ASPEN
BeiGene
Phase 3
Completed
201 enrolled
19 charts
1 FDA